1. van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. European Journal of Heart Failure. 2014;16(1):103–11. DOI: 10.1002/ejhf.30
2. Fietze I, Laharnar N, Obst A, Ewert R, Felix SB, Garcia C et al. Prevalence and association analysis of obstructive sleep apnea with gender and age differences - Results of SHIP-Trend. Journal of Sleep Research. 2019;28(5):e12770. DOI: 10.1111/jsr.12770
3. Butt M, Dwivedi G, Khair O, Lip GYH. Obstructive sleep apnea and cardiovascular disease. International Journal of Cardiology. 2010;139(1):7–16. DOI: 10.1016/j.ijcard.2009.05.021
4. Тюрин В.П., Савчук О.В., Проскурнова В.В., Добриков Е.А., Кулагина А.М. Синдром обструктивного апноэ сна, как независимый предиктор сердечно-сосудистой смертности. Вестник НМХЦ им. Н.И. Пирогова. 2020;15(2):126-8. DOI: 10.25881/BPNMSC.2020.95.30.022
5. Евлампиева Л.Г., Ярославская Е.И., Харац В.Е. Взаимосвязь синдрома обструктивного апноэ сна и факторов сердечно-сосудистого риска. Сибирский журнал клинической и экспериментальной медицины. 2021;36(1):58-65. DOI: 10.29001/2073-8552-2021-36-1-58-65
6. Mentz RJ, Fiuzat M. Sleep-Disordered Breathing in Patients with Heart Failure. Heart Failure Clinics. 2014;10(2):243–50. DOI: 10.1016/j.hfc.2013.10.001
7. Kasai T, Bradley TD. Obstructive Sleep Apnea and Heart Failure. Journal of the American College of Cardiology. 2011;57(2):119–27. DOI: 10.1016/j.jacc.2010.08.627
8. Kheirandish-Gozal L, Gozal D. Obstructive Sleep Apnea and Inflammation: Proof of Concept Based on Two Illustrative Cytokines. International Journal of Molecular Sciences. 2019;20(3):459. DOI: 10.3390/ijms20030459
9. Sozer V, Kutnu M, Atahan E, Calıskaner Ozturk B, Hysi E, Cabuk C et al. Changes in inflammatory mediators as a result of intermittent hypoxia in obstructive sleep apnea syndrome. The Clinical Respiratory Journal. 2018;12(4):1615–22. DOI: 10.1111/crj.12718
10. Bayés-Genis A, González A, Lupón J. ST2 in Heart Failure: The Lungs Claim Their Contribution. Circulation: Heart Failure. 2018;11(12):e005582. DOI: 10.1161/CIRCHEARTFAILURE.118.005582
11. Najjar E, Faxén UL, Hage C, Donal E, Daubert J-C, Linde C et al. ST2 in heart failure with preserved and reduced ejection fraction. Scandinavian Cardiovascular Journal. 2019;53(1):21–7. DOI: 10.1080/14017431.2019.1583363
12. Dalal JJ, Digrajkar A, Das B, Bansal M, Toomu A, Maisel AS. ST2 elevation in heart failure, predictive of a high early mortality. Indian Heart Journal. 2018;70(6):822–7. DOI: 10.1016/j.ihj.2018.08.019
13. Richards AM. ST2 and Prognosis in Chronic Heart Failure. Journal of the American College of Cardiology. 2018;72(19):2321–3. DOI: 10.1016/j.jacc.2018.08.2164
14. Aimo A, Vergaro G, Passino C, Ripoli A, Ky B, Miller WL et al. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure. 2017;5(4):280–6. DOI: 10.1016/j.jchf.2016.09.010
15. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013;62(16):e147-239. DOI: 10.1016/j.jacc.2013.05.019
16. McCarthy CP, Januzzi JL. Soluble ST2 in Heart Failure. Heart Failure Clinics. 2018;14(1):41–8. DOI: 10.1016/j.hfc.2017.08.005
17. Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA et al. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circulation: Heart Failure. 2016;9(1):e002551. DOI: 10.1161/CIRCHEARTFAILURE.115.002551
18. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure. 2011;4(2):180–7. DOI: 10.1161/CIRCHEARTFAILURE.110.958223
19. Gabryelska A, Kuna P, Antczak A, Białasiewicz P, Panek M. IL-33 Mediated Inflammation in Chronic Respiratory Diseases – Understanding the Role of the Member of IL-1 Superfamily. Frontiers in Immunology. 2019;10:692. DOI: 10.3389/fimmu.2019.00692
20. Bajwa EK, Mebazaa A, Januzzi JL. ST2 in Pulmonary Disease. The American Journal of Cardiology. 2015;115(7):44B-47B. DOI: 10.1016/j.amjcard.2015.01.040
21. Васюк Ю.А., Копеева М.В., Корнеева О.Н. Рекомендации по количественной оценке структуры и функции камер сердца. Российский кардиологический журнал. 2012;17(3):1-28
22. Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD et al. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension. Chest. 2018;154(1):126–35. DOI: 10.1016/j.chest.2018.01.009
23. Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, Rahimi HR, Tajfard M, Ferns G. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. Journal of Cellular Physiology. 2018;233(11):8508–25. DOI: 10.1002/jcp.26791
24. Tugcu A, Guzel D, Yildirimturk O, Aytekin S. Evaluation of Right Ventricular Systolic and Diastolic Function in Patients with Newly Diagnosed Obstructive Sleep Apnea Syndrome without Hypertension. Cardiology. 2009;113(3):184–92. DOI: 10.1159/000193146
25. Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 Axis in Organ Fibrosis. Frontiers in Immunology. 2018;9:2432. DOI: 10.3389/fimmu.2018.02432
26. Ragusa R, Cabiati M, Guzzardi MA, D’Amico A, Giannessi D, Del Ry S et al. Effects of obesity on IL-33/ST2 system in heart, adipose tissue and liver: study in the experimental model of Zucker rats. Experimental and Molecular Pathology. 2017;102(2):354–9. DOI: 10.1016/j.yexmp.2017.03.002
27. Бродовская Т.О., Грищенко О.О., Гришина И.Ф., Перетолчина Т.Ф. Особенности ремоделирования сердца у пациентов с синдромом обструктивного апноэ сна и его коморбидной ассоциацией с ожирением в контексте концепции раннего старения. Российский кардиологический журнал. 2019;4:27-34. DOI: 10.15829/1560-4071-2019-4-27-34
28. Vianello E, Dozio E, Tacchini L, Frati L, Corsi Romanelli MM. ST2/IL-33 signaling in cardiac fibrosis. The International Journal of Biochemistry & Cell Biology. 2019;116:105619. DOI: 10.1016/j.biocel.2019.105619
29. Sharim J, Daniels LB. Soluble ST2 and Soluble Markers of Fibrosis: Emerging Roles for Prognosis and Guiding Therapy. Current Cardiology Reports. 2020;22(6):41. DOI: 10.1007/s11886-020-01288-z